| Literature DB >> 27532814 |
Santosh Mathapati1,2, Richard Siller1,2, Agata A R Impellizzeri1,3, Max Lycke1, Karianne Vegheim4, Runar Almaas4, Gareth J Sullivan1,2,5.
Abstract
Hepatocyte-like cells (HLCs) generated in vitro from human pluripotent stem cells (hPSCs) provide an invaluable resource for basic research, regenerative medicine, drug screening, toxicology, and modeling of liver disease and development. This unit describes a small-molecule-driven protocol for in vitro differentiation of hPSCs into HLCs without the use of growth factors. hPSCs are coaxed through a developmentally relevant route via the primitive streak to definitive endoderm (DE) using the small molecule CHIR99021 (a Wnt agonist), replacing the conventional growth factors Wnt3A and activin A. The small-molecule-derived DE is then differentiated to hepatoblast-like cells in the presence of dimethyl sulfoxide. The resulting hepatoblasts are then differentiated to HLCs with N-hexanoic-Tyr, Ile-6 aminohexanoic amide (Dihexa, a hepatocyte growth factor agonist) and dexamethasone. The protocol provides an efficient and reproducible procedure for differentiation of hPSCs into HLCs utilizing small molecules. © 2016 by John Wiley & Sons, Inc.Entities:
Keywords: definitive endoderm; hESCs; hepatocyte; hiPSCs; small molecules
Mesh：
Substances：
Year: 2016 PMID： 27532814 DOI： 10.1002/cpsc.13
Source DB: PubMed Journal: Curr Protoc Stem Cell Biol ISSN： 1938-8969